Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
43.4M
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
17.9M
-
Shares change
-
-274K
-
Total reported value, excl. options
-
$223M
-
Value change
-
-$3.84M
-
Put/Call ratio
-
7.63
-
Number of buys
-
48
-
Number of sells
-
-27
-
Price
-
$12.51
Significant Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) as of Q4 2020
102 filings reported holding CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share as of Q4 2020.
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.9M shares
of 43.4M outstanding shares and own 41.13% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (2.51M shares), BlackRock Inc. (2.16M shares), Corriente Advisors, LLC (1.92M shares), Slate Path Capital LP (1.48M shares), STATE STREET CORP (1.39M shares), Prosight Management, LP (907K shares), MORGAN STANLEY (544K shares), GOLDMAN SACHS GROUP INC (513K shares), Woodline Partners LP (510K shares), and Robertson Stephens Wealth Management, LLC (484K shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.